Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 841 of 5804
-
Donor immune cells show promise against returning blood cancers
Disease control OngoingPatients have a type of lymph gland cancer called Non-Hodgkin Lymphoma (NHL), acute lymphocytic leukemia (ALL) or chronic lymphocytic leukemia (CLL) (these diseases will be referred to as "lymphoma" or "leukemia"). The lymphoma or leukemia has come back or has not gone away after…
Phase: PHASE1 • Sponsor: Baylor College of Medicine • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
New hope for fanconi anemia: safer stem cell transplant trial opens
Disease control Recruiting nowThe purpose of this study is to determine whether the use of lower doses of busulfan and the elimination of cyclosporine will further reduce transplant-related side effects for patients with Fanconi Anemia (FA). Patients will undergo a transplant utilizing mis-matched related or …
Phase: PHASE2 • Sponsor: Children's Hospital Medical Center, Cincinnati • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
Double-Dose chemo strategy shows promise against pancreatic cancer
Disease control CompletedThis phase II trial studies how well combination chemotherapy before and after surgery works in treating patients with localized pancreatic cancer. Drugs used in chemotherapy, such as leucovorin calcium, fluorouracil, irinotecan hydrochloride, and oxaliplatin, work in different w…
Phase: PHASE2 • Sponsor: Yale University • Aim: Disease control
Last updated Jun 27, 2026 09:11 UTC
-
Triple drug cocktail takes on tough melanoma
Disease control OngoingThis phase I/II trial studies the side effects and best dose of dabrafenib, trametinib, and navitoclax and to see how well they work in treating patients with BRAF mutant melanoma or solid tumors that has spread from where it first started (primary site) to other places in the bo…
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Cancer drug shows promise in slowing rare tumor growth
Disease control CompletedThis randomized phase III trial compares the effects, good and/or bad, of sorafenib tosylate in treating patients with desmoid tumors or aggressive fibromatosis. Sorafenib tosylate may stop the growth of tumor cells by blocking some of the proteins needed for cell growth. \[Fundi…
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New hope for advanced colon cancer: immune drug shrinks tumors in genetic subtype
Disease control CompletedThe purpose of this study is to examine if Nivolumab by itself, or Nivolumab in combination with other anti-cancer drugs, will result in meaningful tumor size reduction, in participants with colon cancer that has come back or has spread, and who have a specific biomarker in their…
Phase: PHASE2 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
Heart shield for young cancer survivors: new study tests dexrazoxane
Disease control Recruiting nowThis clinical trial studies the effects of dexrazoxane hydrochloride on biomarkers associated with cardiomyopathy and heart failure after cancer treatment. Studying samples of blood in the laboratory from patients receiving dexrazoxane hydrochloride may help doctors learn more ab…
Sponsor: Children's Oncology Group • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
Stem cells aim to tame heart failure in landmark trial
Disease control CompletedThe primary objective of this study is to determine whether transendocardial delivery of allogeneic human bone marrow-derived mesenchymal precursor cells (MPCs \[rexlemestrocel-L\]) is effective in the treatment of chronic heart failure (HF) due to left ventricular (LV) systolic …
Phase: PHASE3 • Sponsor: Mesoblast, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Less invasive Stent-Graft aims to fix dangerous aortic bulges
Disease control Recruiting nowThe purpose of this study is to gather safety and effectiveness of the Zenith t-Branch and customized physician-specified stent-graft with a combination of fenestrations and/or branches to repair aortic aneurysm.
Phase: NA • Sponsor: Baylor College of Medicine • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
New pill combo shows promise for cystic fibrosis patients
Disease control CompletedThe objective of this study was to evaluate the safety and efficacy of VX-661in combination with ivacaftor in participants with cystic fibrosis (CF) who are homozygous for F508del cystic fibrosis transmembrane conductance regulator (CFTR) mutation
Phase: PHASE2 • Sponsor: Vertex Pharmaceuticals Incorporated • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
Custom stent grafts offer new hope for High-Risk aneurysm patients
Disease control Recruiting nowThe purpose of this study is to evaluate the safety and efficacy of custom made devices, Zenith t-Branch devices and physician modification of FDA approved off-the-shelf endovascular grafts in the treatment of patients with complex abdominal aneurysms, aortoiliac aneurysms, thora…
Phase: NA • Sponsor: Andres Schanzer • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
New drug combo aims to stop liver cancer recurrence in transplant patients
Disease control ENROLLING_BY_INVITATIONThis study is a prospective Phase IV study to determine if the use of Everolimus results in lower liver tumor recurrence and improved patient and graft survival after liver transplant for hepatocellular carcinoma (HCC). The immunosuppressive comparators will be Everolimus and Tac…
Phase: PHASE4 • Sponsor: Baylor Research Institute • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New pill targets rare gene mutation in Hard-to-Treat blood cancers
Disease control Recruiting nowThe purpose of this Phase I, multicenter study is to evaluate the safety, pharmacokinetics, pharmacodynamics and clinical activity of AG-120 in advanced hematologic malignancies that harbor an IDH1 mutation. The first portion of the study is a dose escalation phase where cohorts …
Phase: PHASE1 • Sponsor: Institut de Recherches Internationales Servier • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Can a drug combo shrink breast tumors better before surgery?
Disease control OngoingThe study is being conducted to determine whether neoadjuvant endocrine therapy with fulvestrant or the combination of anastrozole and fulvestrant, is better than anastrozole when given before surgery to shrink the cancer and stop it from growing. Anastrozole inhibits tumor growt…
Phase: PHASE3 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New hope for advanced lung cancer: durvalumab shows promise in trial
Disease control CompletedA study to assess the Effects of MEDI4736 (Durvalumab) in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer in terms of efficacy, safety and tolerability
Phase: PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
New chemo combo aims to stop leukemia return after transplant
Disease control OngoingThis phase II trial studies how well clofarabine and melphalan before a donor stem cell transplant works in treating patients with a decrease in or disappearance of signs and symptoms of myelodysplasia or acute leukemia (disease is in remission), or chronic myelomonocytic leukemi…
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
Jaw surgery offers new hope for sleep apnea sufferers
Disease control Recruiting nowThis study looks at how jaw surgery called maxillomandibular advancement with counterclockwise rotation affects breathing during sleep in people with moderate to severe obstructive sleep apnea who cannot tolerate standard treatments such as Continous Positive Airway pressure trea…
Phase: NA • Sponsor: Jani Talvilahti • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
Supercharged donor cells take on viruses after transplant
Disease control Recruiting nowIn this research study, the investigators want to learn more about the use of donor-derived viral specific T-cells (VSTs) to treat viral infections that occur after allogeneic stem cell transplant. A viral specific T cell is a T lymphocyte (a type of white blood cell) that kills …
Phase: PHASE1, PHASE2 • Sponsor: Children's Hospital Medical Center, Cincinnati • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
Milder transplant method aims to help young patients with rare blood diseases
Disease control Recruiting nowThe objective of this study is to evaluate the efficacy of using a reduced-intensity condition (RIC) regimen with umbilical cord blood transplant (UCBT), double cord UCBT, matched unrelated donor (MUD) bone marrow transplant (BMT) or peripheral blood stem cell transplant (PBSCT) …
Phase: PHASE2 • Sponsor: Paul Szabolcs • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
New drug cocktail aims to crush myeloma early
Disease control CompletedThe purpose is to determine whether induction and consolidation treatment with Carfilzomib, Lenalidomide and Dexamethasone (CRd), within an intensive program, warrant further investigation in clinical trials.
Phase: PHASE2 • Sponsor: University Hospital, Toulouse • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC